Aardvark Therapeutics (AARD) Other Working Capital Changes (2024 - 2026)
Aardvark Therapeutics (AARD) posted Other Working Capital Changes of -$105000.0 for Q1 2026, down 0.96% sequentially from -$104000.0 in Q4 2025, and down 98.11% YoY from -$5.6 million in Q1 2025.
Aardvark Therapeutics (AARD) Other Working Capital Changes (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Other Working Capital Changes for 3 years, with the latest figure at -$105000.0 in Q1 2026.
- Quarterly Other Working Capital Changes fell 98.11% year-over-year to -$105000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$390000.0 (down 74.11% YoY) and the FY2025 annual result came in at -$338000.0, down 70.71% from the prior year.
- Other Working Capital Changes retreated to -$105000.0 in Q1 2026 per AARD's latest filing, from -$104000.0 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $4.4 million in Q1 2025 and troughed at -$254000.0 in Q3 2024.
- A 3-year average of $745000.0 and a median of $332000.0 in 2024 frame the typical range for Other Working Capital Changes.
- The widest YoY moves for Other Working Capital Changes: up 16.85% in 2025, down 200.0% in 2025.
- Over 3 years, Other Working Capital Changes stood at -$89000.0 in 2024, then retreated by 16.85% to -$104000.0 in 2025, then fell by 0.96% to -$105000.0 in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$105000.0, -$104000.0, and -$100000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.50 Bn | 131.65 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.10 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.59 Bn | 60.41 Bn | 1.37 Bn |
| 4 | Moderna | 56.75 Bn | 51.62 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.80 Bn | 9.41 Bn | 668.28 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - |
| 10 | Aardvark Therapeutics | 150.19 Mn | 76.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -105,000.00 |
| Jun 30, 2026 | -105,000.00 |
| Jun 30, 2026 | -105,000.00 |
| Mar 31, 2026 | -105,000.00 |
| Mar 31, 2026 | -105,000.00 |
| Mar 31, 2026 | -105,000.00 |
| Dec 31, 2025 | -104,000.00 |
| Dec 31, 2025 | -104,000.00 |
| Dec 31, 2025 | -104,000.00 |
| Sep 30, 2025 | -100,000.00 |
| Sep 30, 2025 | -100,000.00 |
| Sep 30, 2025 | -100,000.00 |
| Jun 30, 2025 | -81,000.00 |
| Jun 30, 2025 | -81,000.00 |
| Jun 30, 2025 | -81,000.00 |
| Mar 31, 2025 | -53,000.00 |
| Mar 31, 2025 | -53,000.00 |
| Mar 31, 2025 | -53,000.00 |
| Dec 31, 2024 | -89,000.00 |
| Dec 31, 2024 | -89,000.00 |